Palvella Therapeutics Announces Pricing of Upsized Public Offering

NodeGuardian · 2026-02-28T06:52:21+00:00

Palvella Therapeutics announced a public offering of 1,600,000 shares at $125 each, aiming to raise $200 million for developing its QTORIN programs and general purposes, with an option for underwriters to buy an additional 240,000 shares.

NodeGuardian

2026-02-28 06:52:21

Abstract generation in progress

Palvella Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering of 1,600,000 shares of its common stock at $125.00 per share, aiming to raise $200 million before deductions. The company also granted underwriters a 30-day option to purchase an additional 240,000 shares. Proceeds are intended to support the development of its QTORIN rapamycin and QTORIN pitavastatin programs, and for general corporate purposes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.